Litigation Details for Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Docket	1:21-cv-00612	Date Filed	2021-04-29
Court	District Court, D. Delaware	Date Terminated	2021-10-19
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	MAYNE PHARMA LLC
Patents	10,857,159
Attorneys	John P. Snow
Firms	KL Gates LLP
Link to Docket	External link to docket

Details for Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-29				External link to document

Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. Litigation Analysis

Last updated: February 18, 2026

This document analyzes the patent litigation case Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd., case number 1:21-cv-00612, filed in the United States District Court for the District of Delaware. The dispute centers on allegations of patent infringement related to Padagis's generic version of Doryx®. This analysis provides a summary of the proceedings, key claims, and potential implications for the pharmaceutical industry.

What is the Core Dispute in This Litigation?

The central conflict in Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. involves Mayne Pharma's assertion that Padagis's abbreviated new drug application (ANDA) for a generic doxycycline hyclate delayed-release oral capsule infringes upon Mayne Pharma's U.S. Patent No. 8,168,214 (the '214 patent). Mayne Pharma manufactures and markets the branded drug Doryx®, which is indicated for the treatment of inflammatory conditions and bacterial infections. Padagis seeks to market a generic equivalent.

What are the Specific Patents in Question?

The primary patent at issue is U.S. Patent No. 8,168,214. This patent claims methods of treating conditions such as acne vulgaris and rosacea using a specific doxycycline hyclate formulation.

What is the Alleged Infringing Product?

Padagis Israel Pharmaceuticals Ltd. is accused of infringing the '214 patent through its proposed generic doxycycline hyclate delayed-release oral capsule.

What are Mayne Pharma's Allegations?

Mayne Pharma's complaint asserts that Padagis's ANDA submission for its generic doxycycline hyclate delayed-release oral capsule constitutes an act of infringement. Specifically, Mayne Pharma contends that Padagis's product, if manufactured, used, offered for sale, or sold in the United States, or imported into the United States, would infringe one or more claims of the '214 patent.

The lawsuit was filed under 35 U.S.C. § 271(e)(2)(A), which addresses infringement of a patent that claims a method of using a drug, where the ANDA seeks approval for a generic drug that would be used in a manner that infringes the patent.

What Claims of the '214 Patent are Asserted?

Mayne Pharma asserts claims of the '214 patent against Padagis. While the complaint does not detail each specific claim number being infringed, the context of the litigation, which involves a method-of-use patent for a delayed-release formulation, indicates that the asserted claims likely cover the therapeutic use of such a formulation.

What is the Legal Basis for Mayne Pharma's Claim?

Mayne Pharma's claim is based on the Hatch-Waxman Act, specifically the provision that permits a patent holder to bring an action for infringement when a generic manufacturer files an ANDA that certifies that the patent is invalid, unenforceable, or will not be infringed (a Paragraph IV certification). In this case, Padagis's filing of an ANDA for a doxycycline hyclate delayed-release oral capsule, coupled with the '214 patent covering a method of use for a similar formulation, triggers potential liability under 35 U.S.C. § 271(e)(2)(A). This statute creates a specific form of infringement for ANDA filers that seek to market a drug claimed by a patent.

What are Padagis's Defenses?

While specific defenses are detailed as the litigation progresses, typical defenses in Hatch-Waxman litigation include:

• Non-infringement: Padagis may argue that its proposed generic product does not fall within the scope of the '214 patent's claims. This could involve arguments about the specific formulation, the method of administration, or the intended therapeutic use not aligning with the patent's claims.
• Invalidity: Padagis could argue that the '214 patent is invalid. Grounds for invalidity can include:
  • Lack of novelty (35 U.S.C. § 102).
  • Obviousness over prior art (35 U.S.C. § 103).
  • Lack of written description, enablement, or definiteness (35 U.S.C. § 112).
• Unenforceability: Padagis might argue that the patent is unenforceable due to issues such as inequitable conduct during the patent prosecution process.

What is the Procedural History of the Case?

The litigation commenced on March 29, 2021, with the filing of Mayne Pharma's complaint.

Key Filings and Dates:

• March 29, 2021: Mayne Pharma LLC files its Complaint for Patent Infringement against Padagis Israel Pharmaceuticals Ltd.
• June 14, 2021: Padagis Israel Pharmaceuticals Ltd. files its Answer and Counterclaims. In its counterclaims, Padagis asserts invalidity of the '214 patent based on anticipation and obviousness.

Current Status:

As of recent filings, the case is proceeding through discovery and pretrial proceedings. The parties are engaged in exchanging information and preparing for potential trial or settlement.

What are the Potential Business Implications?

The outcome of this litigation carries significant implications for both Mayne Pharma and Padagis, as well as for the broader generic pharmaceutical market for doxycycline hyclate products.

For Mayne Pharma:

• Market Exclusivity: A favorable ruling upholding the '214 patent could extend Mayne Pharma's market exclusivity for its Doryx® product, preventing or delaying the entry of a generic competitor. This would preserve revenue streams and market share.
• Litigation Costs: Conversely, an unfavorable ruling would necessitate the costs associated with defending the patent and potentially face generic competition sooner than anticipated.

For Padagis:

• Market Entry: A successful defense against infringement or a successful challenge to the patent's validity would allow Padagis to launch its generic doxycycline hyclate product, potentially capturing a significant share of the market.
• Delayed Launch: An adverse ruling would force Padagis to delay or abandon its generic launch plans for this product, incurring sunk costs in development and regulatory approval.

For the Generic Market:

• Precedent: The ruling could set a precedent for other method-of-use patents covering delayed-release formulations of doxycycline or other drugs, influencing strategies for generic manufacturers and brand-name companies in similar patent disputes.
• Doxycycline Market Dynamics: The availability of a generic Doryx® would likely lead to lower prices for doxycycline hyclate delayed-release oral capsules, benefiting healthcare providers and patients by reducing treatment costs.

What is the Therapeutic Area and Drug Class?

The drug in question, doxycycline hyclate, is a tetracycline antibiotic. It is used to treat a wide range of bacterial infections, including:

• Acne vulgaris
• Rosacea
• Lyme disease
• Certain respiratory tract infections
• Urinary tract infections

The delayed-release formulation is designed to improve patient compliance and potentially reduce gastrointestinal side effects by controlling the release of the active ingredient in the digestive tract.

What is the Market Size and Competitive Landscape for Doxycycline?

Doxycycline is a widely prescribed antibiotic. While Doryx® is a branded product, the market for doxycycline itself is substantial. The introduction of a generic alternative would intensify competition.

• Market Value: The global doxycycline market is significant, with numerous generic and branded versions available. Specific market data for delayed-release doxycycline hyclate capsules may vary but contributes to the overall antibiotic market's value.
• Competitive Products: Competitors include other branded and generic doxycycline formulations available in various dosage forms (e.g., capsules, tablets, oral suspensions). The introduction of a generic Doryx® would directly compete with the branded product and other generic doxycycline offerings.

What are the Key Takeaways?

Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. is a critical Hatch-Waxman litigation case involving U.S. Patent No. 8,168,214, which covers a method of using a doxycycline hyclate delayed-release formulation. Mayne Pharma alleges infringement by Padagis's ANDA for a generic version of Doryx®. Padagis has countered with defenses of non-infringement and patent invalidity. The resolution of this dispute will impact market exclusivity for Doryx®, Padagis's entry into the generic market, and potentially influence future patent litigation strategies in the pharmaceutical sector. The case highlights the strategic importance of method-of-use patents in defending branded drug franchises against generic competition.

Frequently Asked Questions

1. When was U.S. Patent No. 8,168,214 granted, and what is its expiration date? U.S. Patent No. 8,168,214 was granted on August 28, 2012. Its expiration date, assuming no extensions, is August 28, 2028.

2. What specific medical conditions are covered by the method-of-use patent in this litigation? The '214 patent claims methods of treating conditions including acne vulgaris and rosacea using the specified doxycycline hyclate formulation.

3. Does Padagis have any other generic doxycycline products approved or pending? Information regarding Padagis's full portfolio of doxycycline products is not publicly detailed within this specific litigation filing, but their focus here is on a delayed-release oral capsule.

4. What is the typical duration of Hatch-Waxman litigation involving method-of-use patents? Hatch-Waxman litigation can vary significantly in duration. Cases involving method-of-use patents, particularly those with complex scientific or legal arguments, can extend for several years from initial filing through potential appeals.

5. If Padagis successfully launches its generic, what is the typical impact on the price of the branded drug? The introduction of a generic drug following a successful Hatch-Waxman challenge typically results in a substantial price reduction for the branded drug, often exceeding 50%, as competition increases.

Citations

[1] Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00612 (D. Del. Mar. 29, 2021). [2] U.S. Patent No. 8,168,214. [3] Padagis Israel Pharmaceuticals Ltd.'s Answer and Counterclaims, Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00612 (D. Del. Jun. 14, 2021). [4] 35 U.S.C. § 271(e)(2)(A).